Velusetrag showed accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing in healthy volunteer subjects.<ref>{{cite journal|last2=Camilleri|first2=M|last3=Goldberg|first3=M|last4=Sweetser|first4=S|last5=McKinzie|first5=S|last6=Burton|first6=D|last7=Wong|first7=S|last8=Kitt|first8=MM|last9=Li|first9=YP|year=2010|title=Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation|journal=Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society|volume=22|issue=1|pages=42–9, e7–8|doi=10.1111/j.1365-2982.2009.01378.x|pmc=2905526|pmid=19691492|last1=Manini|first1=ML|last10=Zinsmeister|first10=a. r.|display-authors=8}}</ref> In addition, velusetrag showed accelerated gastric emptying in patients with diabetic or idiopathic gastroparesis. The proportion of patients who experienced at least a 20% improvement is gastric emptying ranged from 20% to 52% for velusetrag dosed patients and 5% for placebo patients.<ref>{{Cite web|url=http://investor.theravance.com/releasedetail.cfm?ReleaseID=913609|title=Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of Gastroparesis in "Poster of Distinction" at Digestive Disease Week (DDW) 2015 (NASDAQ:TBPH)|website=investor.theravance.com|language=en|access-date=2017-05-10}}</ref><ref>{{Cite news|url=https://seekingalpha.com/news/2530306-theravances-velusetrag-performs-well-in-gastroparesis-study|title=Theravance's velusetrag performs well in gastroparesis study|last=House|first=SA Editor Douglas W.|date=2015-05-18|work=Seeking Alpha|access-date=2017-05-10|language=en-US}}</ref>
